Emmaus Life Sciences, Inc. (OTCQB: EMMA) reported a turnaround in profitability for the second quarter of 2026, posting a net income of $1.3 million compared to a net loss of $1.1 million in the same period of 2025. The commercial-stage biopharmaceutical company attributed the shift to a significant increase in net revenues and a reduction in operating expenses following a strategic partnership.

Net revenues for the three months ended June 30, 2026, reached $6.3 million, a 124% increase from $2.8 million in Q2 2025. This growth was driven by the recognition of revenue from an exclusive license agreement with NeoImmuneTech, Inc. (NIT), which became effective on May 15, 2026. Under the deal, Emmaus granted NIT exclusive rights to market, sell, and distribute Endari and generic equivalents in the U.S., its territories, possessions, and Canada. The revenue figure includes upfront cash payments and royalties, partially offset by a decrease in direct Endari sales.

Operational Efficiency

The company reduced total operating expenses to $2.1 million for the quarter, down from $3.0 million in the comparable period last year. Willis Lee, Chairman and Chief Executive Officer, noted that the decrease was primarily due to expenses attributable to the transfer of the company’s sales force to NIT under the license arrangement. Consequently, income from operations swung to a profit of $3.8 million from a loss of $0.4 million in Q2 2025.

However, other expenses increased to $2.5 million from $1.4 million year-over-year. This rise was mainly caused by decreases in gains on lease modifications and changes in the fair value of investments in equity securities. Despite this, the company reported basic earnings per share of $0.02, compared to a loss of $0.02 per share in the prior year period.

What the Numbers Show

The financial results highlight a structural shift in Emmaus’ business model rather than organic product growth. While gross profit expanded significantly to $5.97 million (from $2.67 million in Q2 2025), the company’s direct operational footprint has contracted. The simultaneous drop in operating expenses ($0.9 million reduction) and direct Endari sales indicates that the profitability improvement is largely transactional, stemming from the licensing deal with NIT rather than sustained volume growth in its core sickle cell disease treatment.

Balance Sheet Position

As of June 30, 2026, Emmaus held cash and cash equivalents of $2.8 million, an increase from $2.1 million at the end of December 2025. However, the balance sheet reflects substantial liabilities. Total current liabilities stood at $66.1 million, including $23.5 million in accounts payable and accrued expenses, and $9.2 million in current notes payable. The company reported a stockholders’ deficit of $66.2 million, widening slightly from a deficit of $63.6 million at the start of the year.

The six-month results also showed improvement, with net revenues reaching $8.3 million compared to $5.2 million in the first half of 2025. However, the company still reported a net loss of $2.0 million for the six-month period ended June 30, 2026, compared to a loss of $3.5 million in the same period last year.